期刊文献+

中西药物联合治疗急性髓系白血病48例 被引量:1

Treatment for 48 Cases of Acute Myeloid Leukemia by the Combination of Traditional Chinese and Western Medicine
下载PDF
导出
摘要 目的:观察益气健脾补肾汤联合阿柔比星、阿糖胞苷诱导缓解化疗方案治疗急性髓系白血病(AML)的临床疗效。方法:将96例患者随机分为对照组和观察组各48例,2组均给予阿柔比星联合阿糖胞苷诱导缓解化疗方案。观察组在此基础上给予益气健脾补肾汤,化疗期间,1剂/d,水煎分服。结果:完全缓解率观察组为50.0%,对照组为25.0%,2组比较差异显著(P<0.05)。总有效率观察组为79.2%,对照组为45.8%,2组比较差异显著(P<0.05)。出血、感染、胃肠道反应、骨髓抑制、肝功能异常等不良反应发生率观察组显著低于对照组(P<0.05)。6、12、18个月时复发率对照组为25.0%、54.2%、58.3%,观察组为16.7%、20.8%、20.8%。2组比较差异具有统计学意义(P<0.05)。结论:益气健脾补肾汤联合阿柔比星、阿糖胞苷诱导缓解化疗方案治疗AML疗效确切,复发率低,可以有效降低化疗毒性反应。 Objective:To observe curative effects of tonifying Qi, spleen and kidney decoction, aclarubicin and cytosine arabinoside induction remission chemotherapy in treating acute myeloid leukemia (AML). Methods:All 96 patients were randomized into the control group and the observation group, both groups were given with aclarubicin and cytosine arabinoside induction remission chemotherapy, the observation group took tonifying Qi, spleen and kid-ney decoction orally, one dose each day, during the period of chemotherapy, water decocted and taken twice. Re-sults:Complete remission rate of the observation group was 50.0%, higher than 25.0%of the control group with re-markable difference (P〈0.05). Total effective rate of the observation group was 79.2%, superior to 45.8%of the control group with notable difference (P〈0.05). The observation group was obvisouly lower than the control group in the incidence rate of adverse reaction such as hemorrhage, infection, gastrointestinal reaction, arrest of bone mar-row, abnormal liver function and others (P〈0.05). Relapse rates at the 6th, 12th and 18th month in the control group were 25.0%, 54.2%and 58.3%respectively, higher than 16.7%, 20.8%and 20.8%of the observation group, the dif-ference indicated statistical meaning (P〈0.05). Conclusion:Tonifying Qi, spleen and kidney decoction, aclarubicin and cytosine arabinoside induction remission chemotherapy could obtain definite effects in treating AML with low relapse rate, the therapy could effectively decrease the toxicity of chemotherapy.
作者 马青
出处 《西部中医药》 2014年第8期86-87,共2页 Western Journal of Traditional Chinese Medicine
关键词 髓系白血病 急性 益气健脾补肾汤 阿柔比星 阿糖胞苷 诱导缓解方案 myeloid leukemia,acute tonifying Qi,spleen and kidney decoction aclarubicin cytosine arabinoside induction remission chemotherapy
  • 相关文献

参考文献4

二级参考文献37

  • 1Deschler B,de Witte T,Mertelsmann R,et al.Treatment decisionmaking for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia:problems and approaches. Haematologica,2006,91:1513-1522.
  • 2Kuendgen A,Germing U.Emerging treatment strategies for acute myeloid leukemia(AML) in the elderly.Cancer Treat Revi,2009,35:97-120.
  • 3Vardiman JW,Harris NL,Brunning RD.The World Health Organization (WHO) classification of the myeloid neoplasms.Blood,2002,100:2292-2302.
  • 4Charlson ME,Pompei P,Ales KL,et al.A new method of classifying prognostic comorbidity in longitudinal studies:development and validation.J Chron Dis,1987,40:373-383.
  • 5D(o)hner H,Estey EH,Amadori S,et al.Diagnosis and management of acute myeloid leukemia in adults:recommendations from an international expert panel,on behalf of the European Leukemia Net.Blood,2010,115:453-474.
  • 6Kantarjian H,Ravandi F,O' Brien S,et al.Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.Blood,2010,116:4422-4429.
  • 7Baz R,Rodriguez C,Fu AZ,et al.Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia.Cancer,2007,110:1752-1759.
  • 8Juliusson G,Antunovic P,Derolf A,et al.Age and acute myeloid leukemia:real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood,2009,113:4179-4187.
  • 9R(o)llig C,Thiede C,Gramatzki M,et al.A novel prognostic model in elderly patients with acute myeloid leukemia:results of 909 patients entered into the prospective AML96 trial.Blood,2010,116:971-978.
  • 10Fr(o)hling S,Schlenk RF,Kayser S,et al.Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years:results from AMLSG trial AML HD98-B.Blood,2006,108:3280-3288.

共引文献90

同被引文献21

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部